Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adverse event08.06.01.010--Not Available
Allergic oedema08.01.07.014; 10.01.03.0250.007113%Not Available
Cardiac disorder02.11.01.003--Not Available
Inflammation08.01.05.007; 10.02.01.0890.007113%Not Available
Ischaemia24.04.02.004--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction17.01.02.031; 15.05.06.006--Not Available
Ill-defined disorder08.01.03.049--Not Available
Sensation of foreign body08.01.09.0020.017783%Not Available
Obstructive airways disorder22.03.01.0110.007113%Not Available
Renal impairment20.01.03.010--Not Available
Anaphylactoid shock24.06.02.005; 10.01.07.004--Not Available
Infusion site extravasation12.07.05.008; 08.02.05.0070.024186%
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.007113%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.017783%
Anosognosia19.21.01.004; 17.02.03.010--Not Available
Acute kidney injury20.01.03.0160.091763%
Toxicity to various agents12.03.01.046--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 12.03.01.064; 10.01.01.0210.010670%Not Available
Nasal pruritus22.04.03.0180.015649%Not Available
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.014227%Not Available
Laryngeal discomfort22.12.03.0090.017783%Not Available
Skin plaque23.03.03.0440.010670%Not Available
Blood brain barrier defect24.03.05.014; 17.08.02.0280.014227%Not Available
Contrast media allergy12.02.05.016; 10.01.01.0100.098165%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.014227%Not Available
Pharyngeal swelling22.04.05.028--Not Available
Swelling of eyelid23.04.01.026; 10.01.05.026; 06.04.04.018--Not Available
Symmetrical drug-related intertriginous and flexural exanthema23.03.05.012; 10.01.01.0460.007113%Not Available
Urticaria papular23.04.02.019; 10.01.06.0190.007113%Not Available
The 10th Page    First    Pre   10    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene